H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on AnaptysBio today and set a price target of $59.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar’s rating is based on AnaptysBio’s strategic decision to split its biopharma operations from its royalty assets, which is expected to maximize the value of its substantial royalty streams. The company’s robust royalty foundation is supported by strong sales of GSK’s Jemperli, which is on track to trigger significant milestone payments, and potential future sales of imsidolimab pending FDA approval.
Additionally, AnaptysBio’s pipeline development remains on schedule, with upcoming data readouts for its promising drug candidates. The anticipated topline data for rosnilimab in ulcerative colitis and the ongoing development of ANB033 and ANB101 highlight the company’s commitment to advancing its clinical programs. These factors collectively contribute to the positive outlook and justify the Buy rating for AnaptysBio’s stock.
In another report released yesterday, Barclays also reiterated a Buy rating on the stock with a $78.00 price target.